Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — JP Morgan Healthcare Conference 2022
28 slides from Regeneron Pharmaceuticals's conference presentation, Jan 10, 2022
Slide 1: JP Morgan Healthcare Conference 2022
JP Morgan Healthcare Conference 2022 January 2022 This non - promotional presentation is intended for the investor audience and contains investigational data as well as forward - loo king statements; actual results may vary materially
Slide 2: Forward-looking statements
This presentation includes forward - looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc . (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward - looking statem
Slide 3: JP Morgan 2022 Current Business Drivers
JP Morgan 2022 Current Business Drivers 3 Leonard S. Schleifer MD, PhD Co - Founder, President & Chief Executive Officer
Slide 4: Executing on Our Core Competencies
4 Executing on Our Core Competencies Investing in Regeneron Looking Ahead to the Future Driving continued growth in core franchises Emerging portfolio of immuno - oncology antibodies Leveraging Regeneron technologies in the ongoing fight against infectious diseases driving new breakthroughs and targ
Slide 5: Delivering Results Across the Organization
PN – Prurigo Nodularis ; EoE – Eosinophilic Esophagitis AD – Atopic Dermatitis; CSU – Chronic Spontaneous Urticaria; NSCLC – Non - Small Cell Lung Cancer; wAMD – Wet Age - Related Macular Degeneration Delivering Results Across the Organization 5 Positive Ph3 results in four potential new indications
Slide 6: EYLEA: 10 Years of Patient Impact
The #1 prescribed FDA approved anti - VEGF treatment for retinal disease ▪ 4Q2021 U.S. net product sales of $1.54Bn (+15% YoY)* ▪ FY2021 U.S. net product sales of $ 5.79Bn (+17% YoY)* Continuing to drive future growth ▪ Diabetic eye disease continues to be a significant growth opportunity ▪ Ph3 read
Slide 7: Dupixent: Strong Performance Across All Approved Indications
Dupixent ® : Strong Performance Across All Approved Indications With Significant Opportunity For Sustained Growth 7 Asthma CRSwNP Figures represent U.S. Biologic - eligible target population; Source – Regeneron Internal Epidemiology Data *Target population includes age groups that are not currently
Slide 8: Dupixent: Near- and Long-Term Opportunities to Drive Growth
Dupixent ® : Near - and Long - Term Opportunities to Drive Growth Estimated regulatory submission timeline for new indications 8 Eosinophilic Esophagitis Chronic Spontaneous Urticaria Chronic Inducible Urticaria - Cold Prurigo Nodularis 74k 48k 308k* 25k 2022e Potential indications with POC Other in
Slide 9: Dupixent & Itepekimab COPD Phase 3s Underway
Itepekimab potential also for non - Type 2 COPD In a Ph2 study*, itepekimab demonstrated 42% exacerbation reduction vs. placebo in former smokers, regardless of Type 2 status, with no safety concerns No eosinophil restriction Focus on former smokers Two Ph3 trials ongoing Pivotal data expected 2024
Slide 10: Rapid Mobilization to Address COVID-19
Regulatory Status x EUA granted for ambulatory treatment and in certain post - exposure prophylaxis settings □ EUA under review for pre - exposure prophylaxis and hospitalization x Approved in the EU for treatment and prevention □ Regulatory decision on BLA submission for treatment and prophylaxis (
Slide 11: Strong Financial Position Enabling Critical Investments
Strong Financial Position Enabling Critical Investments Capital allocation priorities reflect business priorities 11 1. Invest in our best - in - class R&D capabilities 2. Pursue and fund business development opportunities to enable and synergize our R&D capabilities and technologies 3. Return cash
Slide 12: JP Morgan 2022 Upcoming Business Drivers
12 George D. Yancopoulos , MD, PhD Co - Founder, President & Chief Scientific Officer JP Morgan 2022 Upcoming Business Drivers
Slide 13: Regeneron Technologies Power Our Pipeline
Regeneron Technologies Power Our Pipeline: TRAPs, Antibodies and Bispecifics 13 xx 9(/2&,*(1( Š 9(/2&,0286( Š 9(/2&,0081( Š 9(/2&,0$% Š VelociT TM 9(/2&,+80 Š 9(/2&, %L Š Protein Expression Sciences Rubine / Marigold / Blue (Late 2016) Protein Expression Sciences Rubine / Marigold / White (Late 2016
Slide 14: Synergistic Collaborations Supercharge Regeneron's Future
$QWLERGLHV %LVSHFLILFV Synergistic Collaborations Supercharge Regeneron’s Future Turnkey Genetics Therapeutics Platforms 14 /HDUQLQJV IURP PRXVH JHQHWLFV 8QORFNLQJ FDSDELOLWLHV RI PRXVH DQG KXPDQ JHQHWLFV WKURXJK ([LVWLQJ 7XUQNH\ 7HFKQRORJLHV %LRORJLFDOV Novel Turnkey Technologies Gene Medicines 75$
Slide 15: REGEN-COV: Addressing Treatment Need and COVID Prevention
5(*(1 &29 Š $GGUHVVLQJ 7UHDWPHQW 1HHG DV ZHOO DV WKH /RQJ 7HUP 2SSRUWXQLW\ IRU &29,' 3UHYHQWLRQ ,I 6$56 &R9 UHPDLQV HQGHPLF ZH DQWLFLSDWH DQ HQGXULQJ QHHG IRU WKH LPPXQRFRPSURPLVHG 15 'HOWD % &XUUHQW 5(*(1 &29 DQWLERGLHV DUH DFWLYH 2PLFURQ % 0XOWLSOH QH[W JHQHUDWLRQ PRQRFORQDO DQWLERGLHV DUH DFWLYH
Slide 16: Regeneron Technologies Enable Rapid Response to Infectious Diseases
Regeneron Technologies Enable Rapid Response to Infectious Diseases 1H[W JHQHUDWLRQ DQWLERGLHV HIIHFWLYHO\ QHXWUDOL]H WKH 6$56 &R9 2PLFURQ YDULDQW DV ZHOO DV RWKHU YDULDQWV RI FRQFHUQ Regeneron technologies have created a library of thousands of mAbs We have identified multiple ‘next generation’ mAb
Slide 17: Continued Progress and Developments Across Oncology Pipeline
‡ )LUVW LQ FODVV OHDGLQJ WUHDWPHQW IRU DGYDQFHG &6&& ‡ $SSURYHG LQ / DGYDQFHG %&& /$* FRPELQDWLRQ ± / PHODQRPD GDWD SUHVHQWHG DW $6&2 ¶ %LR17HFK )L[9D[ FRPELQDWLRQ LQ SRVW 3' PHODQRPD 3K XQGHUZD\ &RQWLQXHG 3URJUHVV 'HYHORSPHQWV $FURVV 2QFRORJ\ 3LSHOLQH Regeneron positioned to enhance and extend trea
Slide 18: Regeneron's Oncology Toolkit Provides Unique Combinatorial Flexibility
9HORF,PPXQH Š $QWLERGLHV /$* *,75 &7/$ /\PSKRPD Multiple Myeloma Ovarian Cancer 5HJHQHURQ ¶ V 2QFRORJ\ 7RRONLW 3URYLGHV 8QLTXH &RPELQDWRULDO )OH[LELOLW\ Bispecifics CD3 Bispecifics CD20 BCMA MUC16 PSMA &RVWLPXODWRU\ %LVSHFLILFV 7$$ 7$$ 08& 360$ (*)5 &ROODERUDWLRQV $GLFHW %LR %LR17HFK 9\ULDG 1\NRGH ,
Slide 19: Bispecifics for Heme-Onc Malignancies: Maturing CD3 Programs
Bispecifics for Heme - Onc Malignancies: Promising Results from Maturing CD3 Programs 19 &RPELQDWLRQV ZLWK FRVWLPXODWRU\ ELVSHFLILFV DQG RWKHU DJHQWV HQWHULQJ FOLQLF VRRQ (IILFDF\ ± (DUO\ GHHS DQG GXUDEOH UHVSRQVHV 255 ZLWK 9*35 RU EHWWHU DW KLJKHU GRVHV PJ RI UHVSRQGHUV ZLWK 9*35 RU EHWWHU ZLWK &5
Slide 20: Bispecifics for Solid Malignancies
¾ (QFRXUDJLQJ HDUO\ VLJQDOV REVHUYHG LQ D KHWHURJHQHRXV RYDULDQ FDQFHU SRSXODWLRQ ¾ 'DWD IURP GRVH HVFDODWLRQ PRQRWKHUDS\ ),+ VWXG\ DQWLFLSDWHG LQ + ¾ 'RVH HVFDODWLRQ ZLWK /,%7$<2 RQJRLQJ %LVSHFLILFV IRU 6ROLG 0DOLJQDQFLHV 3RWHQWLDO WR ([WHQG %HQHILWV RI &KHFNSRLQW ,QKLELWRUV ,QLWLDO 'DWD LQ 20 2XU
Slide 21: Ongoing and Upcoming Oncology Trials
21*2,1* LIBTAYO* $GYDQFHG /XQJ FDQFHU FKHPR FRPER DGMXYDQW &6&& 5(*1 /$* + LIBTAYO* Advanced melanoma REGN6569 (GITR) + LIBTAYO* Solid tumors REGN4018 (MUC16xCD3) + LIBTAYO* 2+ line Ovarian cancer 5(*1 08& [&' + REGN4018 / LIBTAYO* 2+ line Ovarian cancer 5(*1 360$[&' + LIBTAYO* 3+ line Prostate canc
Slide 22: Regeneron Genetics Medicines
Regeneron Genetics Medicines 22 Novel Genetics - based Drug Target Discovery Genetics - based Drug Development & Precision Medicine Leveraging New Turnkey Therapeutic Approaches • RGC discovered >10 novel drug targets • RGC database links drug targets with disease impact, enhancing probability of cl
Slide 23: Regeneron Genetics Medicines: Building the Pipeline for the Future
REGENERON GENETICS MEDICINES 23 Building the Pipeline for the Future ALN - HSD 1 HSD17B13 siRNA • Nonalcoholic Steatohepatitis NTLA - 2001 2 CRISPR/Cas9 • Transthyretin Amyloidosis (ATTR) Clinical Development Pre - IND CEMDISIRAN 1 C5 siRNA • Immunoglobulin A Nephropathy POZELIMAB + CEMDISIRAN 1 C5
Slide 24: Regeneron-Discovered Approved and Investigational Medicines
Regeneron - Discovered, Approved and Investigational Medicines Across a Wide and Diverse Set of Diseases 24 cemiplimab * (PD1) odronextamab (CD20xCD3) cemdisiran ‡ (C5) pozelimab (C5) pozelimab + cemdisiran ‡ (C5xC5) BCMAxCD3 (REGN5458) sarilumab * (IL - 6R) dupilumab* (IL - 4R) cemiplimab* (PD1) al
Slide 25: Multiple Potential FDA Submissions: 2022-2024+
Multiple Potential FDA Submissions: 2022 - 2024+ 25 New Molecule New Indication Odronextamab (CD20xCD3) B Cell NHL (2H22) REGN5458 (BCMAxCD3) R/R Multiple Myeloma (2H22) DUPIXENT* Prurigo Nodularis (1H22) Chronic Obstructive Pulmonary Disease Itepekimab (IL - 33)* REGN1908 - 1909 (Feld1) Cat Allergy
Slide 26: Key Upcoming Milestones
Key Upcoming Milestones (Next 12 months) 26 EYLEA • Ph3 data readout for Aflibercept 8mg formulation Dupixent • Complete regulatory submission for EoE • Additional Phase 3 data readouts for CSU and PN • Regulatory decision for AD in children (6 mo – 5 yrs ) REGEN - COV • FDA decision on BLA for trea
Slide 27: Q&A
Q&A 27 George D. Yancopoulos, MD, PhD Co - Founder, President & Chief Scientific Officer Marion McCourt E VP, Head of Commercial Robert Landry EVP, Chief Financial Officer Leonard S. Schleifer MD, PhD Co - Founder, President & Chief Executive Officer
Slide 28: Reconciliation of Non-GAAP Measure
Reconciliation of Non - GAAP Measure 28 See slide 2 for additional important information regarding non - GAAP financial measures included in this presentation
Regeneron Pharmaceuticals — JP Morgan Healthcare Conference 2022 on 6ix